1. Home
  2. Labeler Index
  3. American Health Packaging
  4. 60687-657
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 13 images provide visual information about the product associated with Levetiracetam NDC 60687-657 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

1000 mg Levetiracetam Tablet Blister - 1000 mg blister

1000 mg Levetiracetam Tablet Blister - 1000 mg blister

1000 mg Levetiracetam Tablets Carton - 1000 mg carton

1000 mg Levetiracetam Tablets Carton - 1000 mg carton

Levetiracetam is a drug that comes in tablet form with each film-coated tablet containing 1000mg of the drug. The package contains 100 tablets arranged in 10 strips of 10 tablets each. The drug is distributed by American Health Packaging and it is important to dispense it with an accompanying medication guide to each patient. The package insert contains complete prescribing information and the drug should be stored in temperatures between 20°C to 25°C. Additionally, the package should be kept out of reach of children. The text also includes the National Drug Code (NDC) and information on the drug's manufacturer.*

500 mg Levetiracetam Tablet Blister - 500 mg blister

500 mg Levetiracetam Tablet Blister - 500 mg blister

This appears to be a label of a medication bottle for a drug called Levetiracetam. The medication comes in two strengths, 500 mg and 750 mg. The label seems to indicate instructions on how to take the medication, what the medication is for, and other logistical information.*

500 mg Levetiracetam Tablets Carton - 500 mg carton

500 mg Levetiracetam Tablets Carton - 500 mg carton

Levetiracetam is a medication that comes in film-coated tablets. Each package has 100 tablets (10 x 10). It is Rx-only medicine which makes it necessary to Have a full prescribing-information. It contains USP Levetiracetam of 500mg. A medication guide is included in the packaging that should be provided to each patient by the dispensa. It should be stored between 20°C and 25°C with a permissible range of 15°C to 30°C. It is important to keep it out of reach of children and to not use it in case of a broken or blistered pack. The manufacturer of the medication is BluePoint Laboratories and is distributed by American Health Packaging from Columbus, Ohio 43217.*

AHP65701

AHP65701

AHP66801

AHP66801

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - Figure 1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - Figure 1

This is a figure from a study depicting the Responder Rate, which shows a 250% reduction from baseline. The figure shows different percentages on the Y-axis and different treatment groups on the X-axis. One treatment group exhibits statistically significant results compared to a placebo group. The graph also mentions Leviaseam 000 oy and Leviaseam 100 ooy.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - Figure 2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - Figure 2

The text describes a chart titled "Figure 2: Responder Rate" that shows the percentage of patients who experienced a 250% reduction from baseline during "Period A" of Study 2. The chart displays results for a placebo group and two groups of patients taking different doses of a medication called Levetiracetam. One of the groups taking Levetiracetam showed a statistically significant improvement in responder rate compared to the placebo group.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - Figure 3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - Figure 3

The text describes Figure 3 showing the responder rate (>50% reduction from baseline) in Study 3. The graph includes two vertical bars representing the placebo (N=104) and Levetiracetam 3000 mg/day (N=180) groups along with percentages on the horizontal axis ranging from 0% to 45%. The Levetiracetam group had a statistically significant response rate compared to the placebo group.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - Figure 4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - Figure 4

Figure 4 displays the Responder Rate for a study, where a reduction of 50% from the baseline was achieved. The percentage of responders was 44.6% for the placebo group and 45% for the group that took Levetiracetam. The graph shows that the Levetiracetam group had a statistically significant result compared to the placebo group.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - Figure 5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - Figure 5

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - Figure 6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - Figure 6

The figure shows the responder rate in reducing the frequency of PGTC seizures per week in Study 7. The graph depicts that patients who received Levetiracetam had a significant reduction in seizures compared to the placebo group.*

Structural Formula - Structure

Structural Formula - Structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.